文献速递细菌感染、耐药与抗菌药物

英国与爱尔兰革兰阴性菌血流感染耐药趋势(2001–2019)

Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

BSAC血流感染耐药监测项目于2001–2019年从英爱医院收集固定配额菌株行中心化MIC测试,并与UKHSA全英格兰血流分离株易感性数据比较。大肠埃希菌与肺炎克雷伯菌在2002–06年对头孢菌素、氟喹诺酮类和庆大霉素耐药率明显上升后趋稳,2015年前后缓慢回升;碳青霉烯酶在所有菌种中仍极罕见。

要点

  • 大肠埃希菌与肺炎克雷伯菌2002–06年头孢菌素、氟喹诺酮类和庆大霉素耐药率明显上升,之后趋稳。
  • 两菌种头孢菌素耐药多由ESBLs(主要为CTX-M型)介导,且常见阿莫西林/克拉维酸耐药。
  • 肠杆菌属与沙雷菌属头孢菌素(多为AmpC去阻遏)和氟喹诺酮耐药下降,碳青霉烯酶极罕见。

核心结论

  • 除大肠埃希菌和肺炎克雷伯菌早期头孢菌素、氟喹诺酮类和庆大霉素耐药上升外,多数菌种无耐药持续上升证据,部分菌种耐药下降。

研究设计与样本

  • BSAC监测项目2001–2019年每年从英爱医院按固定配额收集血流分离株,以琼脂稀释法测MIC,并用协同试验、解读性阅读和PCR研究耐药机制。
  • UKHSA同步收集英格兰所有血流分离株的本地药敏数据,两者结果经复核比较。

主要发现

  • 大肠埃希菌现占全部血流感染>30%,其2002–06年头孢菌素、氟喹诺酮类和庆大霉素耐药明显上升,随后小幅下降并趋稳,2015年前后非常缓慢回升;肺炎克雷伯菌呈相似模式。
  • 两菌种头孢菌素耐药多涉及ESBLs(主要为CTX-M型),且阿莫西林/克拉维酸耐药常见。
  • 肠杆菌属和沙雷菌属头孢菌素耐药(多为AmpC介导)及氟喹诺酮耐药下降,可能反映用量和选择压力减少。
  • 变形杆菌属变化少;BSAC收集中奇异变形杆菌优势增加未获UKHSA数据确认;铜绿假单胞菌耐药不常见且两数据集均无明显时间变化。
  • 碳青霉烯酶在所有菌种中仍极罕见;新型在研药物覆盖多种耐药类型,但无一覆盖全部类型。

临床怎么用

  • 经验性用药应关注大肠埃希菌和肺炎克雷伯菌ESBLs(CTX-M型)及阿莫西林/克拉维酸耐药的高背景。
  • 碳青霉烯酶仍极罕见,不应据此普遍扩大碳青霉烯类使用。
  • 新型在研药物覆盖多种耐药类型但无一覆盖全部,选择时需明确耐药机制。

局限性

  • BSAC监测为固定配额采样,非全部血流分离株,可能与UKHSA全英格兰数据存在选择差异。
  • 原文提及奇异变形杆菌优势增加未获UKHSA数据确认,提示两数据集间存在不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The BSAC Bacteraemia Resistance Surveillance Programme collected isolates from UK and Irish hospitals for central testing. Concurrent UKHSA surveillance collected English hospitals' own susceptibility data. Results were reviewed and compared. METHODS: The BSAC surveillance collected fixed quotas of isolates per site annually from 2001 to 2019. MIC testing was by BSAC agar dilution. Resistance mechanisms were investigated by synergy tests, interpretive reading and PCR. The UKHSA seeks data on all bacteraemia isolates in England. RESULTS: For Escherichia coli, which now causes >30% of all bacteraemias, there were marked early (2002-06) rises in resistance to cephalosporins, fluoroquinolones and gentamicin, followed by small falls, stabilization, then from around 2015, very slow rises, with similar patterns seen for Klebsiella pneumoniae. Most cephalosporin resistance in these two species involved ESBLs, principally CTX-M types. Both species had frequent co-amoxiclav resistance. Cephalosporin resistance-mostly AmpC-mediated-declined in Enterobacter and Serratia spp., as did fluoroquinolone resistance, likely reflecting reduced use and selection pressure. Proteeae showed few changes; increasing dominance of Proteus mirabilis in the BSAC collection was not confirmed by the UKHSA dataset. Resistance in Pseudomonas aeruginosa was uncommon and showed little temporal change in either dataset. Carbapenemases remained extremely rare in all species. Newer and developmental agents covered many resistance types, but none covered all types. CONCLUSIONS: Except for early rises of cephalosporin, fluoroquinolone and gentamicin resistance in E. coli and K. pneumoniae, there was little evidence for rising resistance and some evidence of declining resistance, notably in species where it predominantly involves AmpC derepression.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Reynolds R, Mushtaq S, Hope R, et al. Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019. J Antimicrob Chemother. 2025. PMID: 41140275. doi:10.1093/jac/dkaf250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。